What can we expect from prophylactic implantable defibrillators?

American Journal of Cardiology

Volumn 80, Issue 5 B, 1997, Pages

  Wilber, David J ^a   Kall, John G ^a   Kopp, Douglas E ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PROPRANOLOL; SOTALOL;

CLINICAL TRIAL; CONFERENCE PAPER; DEFIBRILLATOR; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE TACHYCARDIA; HIGH RISK POPULATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ISCHEMIC HEART DISEASE; META ANALYSIS; MORTALITY; ORAL DRUG ADMINISTRATION; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; RISK BENEFIT ANALYSIS; SUDDEN DEATH; SURVIVAL;

EID: 0030864067     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00479-7     Document Type: Conference Paper

References (54)

1. Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death: epidemiology, transient risk, and intervention assessment. Ann Intern Med. 119:1993;1187-1199.
2. Liberthson RR, Nagel EL, Hirschman JC, et al. Pathophysiologic observations in prehospital ventricular fibrillation and sudden cardiac death. Circulation. 49:1974;790-797.
3. Reichenbach DD, Moss NS, Meyer E. Pathology of the heart in sudden cardiac death. Am J Cardiol. 39:1977;865-869.
4. Kannel WB, Doyle JT, McNamara PM, et al. Precursors of sudden coronary death: factors related to the incidence of sudden death. Circulation. 51:1975;606-611.
5. Rosenberg HM, Kleggs AJ. Trends in cardiovascular mortality with a focus on ischemic heart disease. DHEW, NIH Publication No. 79-1610. 1979;US Government Printing Office, Washington, DC.
6. Eisenberg MS, Horwood BT, Cummins RO, et al. Cardiac arrest and resuscitation: a tale of 29 cities. Ann Emerg Med. 19:1990;179-186.
7. Valenzuela TD, Spaite DW, Meislin HW, et al. Case and survival definitions in out-of-hospital cardiac arrest. Effect on survival rate calculation. JAMA. 267:1992;272-274.
8. Weaver WD, Hill D, Fahrenbruch CE, et al. Use of the automatic external defibrillator in the management of out-of-hospital cardiac arrest. N Engl J Med. 319:1988;661-666.
9. Risk Stratification after Myocardial Infarction. N Engl J Med. 309:1983;331-336.
10. Volpi A, DeVita C, Franzosi MG, et al. Determinants of 6-month mortality in survivors of myocardial infarction after thrombolysis. Circulation. 88:1993;416-429.
11. Bigger JT, Fleiss JL, Kleiger R, et al. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation. 69:1984;250-258.
12. Ahnve S, Gilpin E, Henning H, et al. Limitations and advantages of the ejection fraction for defining high risk after acute myocardial infarction. Am J Cardiol. 58:1986;872-878.
13. Mukharji J, Rude RE, Poole WK, et al. Risk factors for sudden death after acute myocardial infarction: 2-year follow up. Am J Cardiol. 54:1984;31-36.
14. Maggioni AP, Zuanetti G, Franzosi MG, et al. Prevalence and prognostic significance of ventricular arrhythmias after acute myocardial infarction in the fibrinolytic era: GISSI-2 results. Circulation. 87:1993;312-322.
15. Zaret BL, Wackers FJ, Terrin M, et al. Does left ventricular ejection fraction following thrombolytic therapy have the same prognostic impact described in the prethrombolytic era? (Abstr.). J Am Coll Cardiol. 17:1991;214A.
16. The effects of tissue plasminogen activator, streptokinase or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 329:1993;1615-1622.
17. Hinkle LE, Thaler HT. Clinical classification of cardiac deaths. Circulation. 65:1982;457-464.
18. Marcus FI, Cobb LA, Edwards JE, et al. Mechanism of death and prevalence of myocardial ischemic symptoms in the terminal event after acute myocardial infarction. Am J Cardiol. 61:1988;8-15.
19. Yusuf S, Peto R, Lewis J, et al. β blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 27:1985;335-371.
20. Goldman L, Sia B, Cook EF, et al. Costs and effectiveness of routine therapy with long-term β-adrenergic antagonists after acute myocardial infarction. N Engl J Med. 319:1988;152-157.
21. Kendall MJ, Lynch KP, Hjalmarson A, et al. β blockers and sudden cardiac death. Ann Intern Med. 123:1995;358-367.
22. Furberg CD, Hawkins CM, Lichstein E. Effect of propranolol in postinfarction patients with mechanical or electrical complications. Circulation. 69:1984;761-765.
23. The β blocker pooling project: subgroup findings from randomized trials in postinfarction patients. Eur Heart J. 9:1988;8-16.
24. Held P. Effects of β blockers on ventricular dysfunction after myocardial infarction: tolerability and side effects. Am J Cardiol. 71:((suppl)):1993;39C-44C.
25. Kennedy HL, Brooks MM, Barker AH, et al. β-blocker therapy in the cardiac arrhythmia suppression trial. Am J Cardiol. 74:1994;674-680.
26. Lichstein E, Hager WD, Gregory JJ, et al. Relationship between β-adrenergic blocker use, various correlates of left ventricular function and the chance of developing congestive heart failure. J Am Coll Cardiol. 16:1990;1327-1332.
27. Soumerai SB, McLaughlin TJ, Spigelman D, et al. Adverse outcomes of underuse of β blockers in elderly survivors of acute myocardial infarction. JAMA. 277:1997;115-121.
28. Kennedy HL, Rosenson RS. Physician use of β-adrenergic blocking therapy: a changing perspective. J Am Coll Cardiol. 26:1995;547-552.
29. Latini R, Maggioni AP, Flather M, et al. ACE inhibitor use in patients with myocardial infarction: summary of evidence from clinical trials. Circulation. 92:1995;3132-3137.
30. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial (SAVE). N Engl J Med. 327:1992;669-677.
31. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 342:1993;821-828.
32. The trandolapril cardiac evaluation (TRACE) study: rationale, design, and baseline characteristics of the screened population. Am J Cardiol. 73:((suppl)):1994;44C-50C.
33. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N Engl J Med. 327:1992;685-691.
34. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-nitrate in the treatment of chronic congestive heart failure. N Engl J Med. 325:1991;303-310.
35. collaborative overview of randomized trials of antiplatelet therapy. Br Med J. 308:1994;81-89.
36. Nademanee K, Singh BN, Stevenson WG, Weiss JN. Amiodarone and post-MI patients. Circulation. 88:1993;764-774.
37. Burkhart F, Pfisterer M, Kiowski W, et al. Effect of antiarrhythmic treatment on mortality in survivors of myocardial infarction with asymptomatic cardiovascular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol. 16:1990;1711-1718.
38. Cairns JA, Connolly SJ, Gent M, et al. Post-myocardial infarction mortality in patients with premature ventricular depolarizations: Canadian Amiodarone Myocardial Infarction Arrhythmia pilot study. Circulation. 84:1991;550-557.
39. Ceremuzynski Z, Kleczar E, Krzeminka-Pakula M, et al. Effect of amiodarone on mortality after myocardial infarction. J Am Coll Cardiol. 20:1992;1056-1062.
40. Navarro-Lopez F, Cosin J, Marrugat J, et al. Comparison of the effects of amiodarone versus metoprolol on the frequency of ventricular arrhythmias and on mortality after acute myocardial infarction. Am J Cardiol. 72:1993;1243-1248.
41. Zarembski DG, Nolan PE, Slack MK, et al. Empiric long-term amiodarone prophylaxis following myocardial infarction. Arch Intern Med. 153:1993;2661-2667.
42. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, Massie BM, Colling C, Lazzeri D. Amiodarone in patients with congestive heart failure and ventricular arrhythmia. N Engl J Med. 333:1995;77-82.
43. Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet. 349:1997;675-681.
44. Julian DG, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwartz PJ, Simon P. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet. 349:1997;667-674.
45. Mason JW. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med. 329:1993;452-458.
46. Reiffel JA, Hahn E, Hartz V. Was the superiority of sotalol in the ESVEM Trial due to its β-blocking effect? (Abstr.). PACE. 18:1995;811.
47. Julian DG, Jackson FS, Prescott RJ, et al. Controlled trial of sotalol for one year after myocardial infarction. Lancet. i:1982;1142-1147.
48. The effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet. 348:1996;7-12.
49. Moss AJ, Hall J, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary artery disease at high risk for ventricular arrhythmia. N Engl J Med. 335:1996;1933-1940.
50. Friedman PL, Stevenson WG. Unsustained ventricular tachycardia - to treat or not to treat. (Editorial). N Engl J Med. 335:1996;1984-1985.
51. Wilber DJ, Olshansky B, Moran JF, Scanlon PJ. Electrophysiologic testing and nonsustained ventricular tachycardia: use and limitations in patients with coronary artery disease and impaired ventricular function. Circulation. 82:1990;350-358.
52. Heart and Stroke Facts: 1996 Statistical Supplement. 1996;American Heart Association, Dallas.
53. Josephson ME, Lee KL, Pryor DB, et al. Prevention of sudden death in patients with coronary artery disease: the multicenter unsustained tachycardia trial (MUSTT). Prog Cardiovasc Dis. 36:1993;215-226.
54. The Coronary Artery Bypass Graft (CABG) Patch Trial. Prog Cardiovasc Dis. 36:1993;97-114.